Thymosin Alpha-1 10mg

Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is approved in over 35 countries under the brand name Zadaxin for hepatitis B and as an immune adjuvant, making it one of the most clinically validated immunomodulatory peptides in existence. Ta1 acts as a potent immune modulator through multiple mechanisms. It activates dendritic cells via Toll-like receptor 9 (TLR9), enhancing their ability to present antigens and stimulate T-cell responses. It promotes differentiation of CD4+ and CD8+ T-cells, enhances natural killer (NK) cell cytotoxicity, and increases MHC class I expression on tumor cells, making them more visible to the immune system. Importantly, Ta1 modulates rather than simply stimulates immunity — it can upregulate suppressed immune responses while dampening excessive inflammatory reactions. Clinically, Ta1 has been most extensively studied in chronic hepatitis B, where it has shown the ability to increase seroconversion rates and suppress viral replication. It has also been investigated as a vaccine adjuvant (particularly for influenza in the elderly), in combination with interferon-alpha for hepatitis C, and as an immunomodulator in cancer treatment protocols. More recently, it was investigated during the COVID-19 pandemic for its ability to restore lymphocyte counts in severely lymphopenic patients.

Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is approved in over 35 countries under the brand name Zadaxin for hepatitis B and as an immune adjuvant, making it one of the most clinically validated immunomodulatory peptides in existence. Ta1 acts as a potent immune modulator through multiple mechanisms. It activates dendritic cells via Toll-like receptor 9 (TLR9), enhancing their ability to present antigens and stimulate T-cell responses. It promotes differentiation of CD4+ and CD8+ T-cells, enhances natural killer (NK) cell cytotoxicity, and increases MHC class I expression on tumor cells, making them more visible to the immune system. Importantly, Ta1 modulates rather than simply stimulates immunity — it can upregulate suppressed immune responses while dampening excessive inflammatory reactions. Clinically, Ta1 has been most extensively studied in chronic hepatitis B, where it has shown the ability to increase seroconversion rates and suppress viral replication. It has also been investigated as a vaccine adjuvant (particularly for influenza in the elderly), in combination with interferon-alpha for hepatitis C, and as an immunomodulator in cancer treatment protocols. More recently, it was investigated during the COVID-19 pandemic for its ability to restore lymphocyte counts in severely lymphopenic patients.

Clinical protocols typically use 1.6 mg subcutaneously twice weekly. Hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months. Vaccine adjuvant studies used single 1.6 mg doses before vaccination.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.